Showing 7331-7340 of 7485 results for "".
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- NeoStrata Launches SKIN ACTIVE Perfecting Peelhttps://practicaldermatology.com/news/20120918-neostrata_launches_skin_active_perfecting_peel/2459736/NeoStrata Company, Inc., the creators of the original glycolic acid peel, introduced the Perfecting Peel to SKIN ACTIVE, its line of antiaging skincare. SKIN ACTIVE Perfecting Peel is formulated with a 20% alpha hydroxy acid blend of 10% citric
- Nomir Medical Submits 510(k) Application to FDA for Onychomycosishttps://practicaldermatology.com/news/20120911-nomir_medical_announces_510k_application_to_fda_for_onychomycosis/2459742/Nomir Medical Technologies, Inc. submitted a 510(k) application to the US Food and Drug Administration (FDA) for the indication of temporary increase of clear nail in patients with onychomycosis (toenail fungus). This 510(k) submission to FDA
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- Study: HA Fillers Effective for Full-face Rejuvenationhttps://practicaldermatology.com/news/20120824-study_ha_fillers_effective_for_full-face_rejuvenation/2459747/In subjects with multiple indications, full-face rejuvenation using hyaluronic acid (HA) fillers” provided effective, safe, and satisfactory results,” one of the first studies of its kind concludes. (Dermatol Surg;38(7 Pt 2):1153-61) The six-month study involved 77 subjects treated with five differe
- Abbott 2Q Profit Beats Expectations, Humira Sales Growhttps://practicaldermatology.com/news/20120802-abbott_2q_profit_beats_expectations_humira_sales_grow/2459757/Abbott Laboratories announced that second-quarter earnings narrowly beat estimates, fueled by the continued growth of its drug Humira. The company said net income for the quarter declined to $1.75 billion, or $1.08 per share, from $1.94 b
- CryoShape LTD Launches One-time Scar-freezing Treatmenthttps://practicaldermatology.com/news/20120802-cryoshape_ltd_launches_one-time_scar-freezing_treatment/2459758/CryoShape LTD introduced CryoShape, a new technology to reduce or eliminate keloid and hypertrophic scars, at the Aesthetic Plastic Surgery/Anti-Aging Medicine: The Next Generation Symposium in New York City July 20-22, 2012. The product uses a
- National Rosacea Society to Host 20th Anniversary Galahttps://practicaldermatology.com/news/20120730-national_rosacea_society_to_host_20th_anniversary_gala/2459759/The National Rosacea Society is hosting a 20th Anniversary Gala Celebration and Dinner on August 17, 2012, from 6-9pm at the Boston Sheraton Hotel during the summer AAD meeting to give thanks to the countless healthcare professionals who have helped improve the quality of life for rosacea patients w
- Sandoz Completes Acquisition of Fougera Pharmaceuticalshttps://practicaldermatology.com/news/20120727-sandoz_completes_acquisition_of_fougera_pharmaceuticals/2459760/Sandoz has completed its USD $1.525 billion acquisition of specialty dermatology company Fougera Pharmaceuticals. Combined with Sandoz's existing generic dermatology franchise, this acquisition positions Sandoz as the new #1 in generic dermatology